Researchers of a study examined the incidence of tardive dyskinesia (TD) between long-acting injectable antipsychotics (LAI-APs) and equivalent oral antipsychotics (O-APs), LAI first-generation antipsychotics and LAI second-generation antipsychotics (LAI-SGAs), as well as individual LAI-APs using the Japanese Adverse Drug Event Report with data from April 2004 to February 2021. Researchers included 8,425 patients in the study. It was found that LAI-APs, especially LAI-SGAs, compared with O-APs may be linked to a lower TD risk.

Reference: Misawa F, Fujii Y, Takeuchi H. Tardive Dyskinesia and Long-Acting Injectable Antipsychotics: Analyses Based on a Spontaneous Reporting System Database in Japan. J Clin Psychiatry. 2022;83(5):21m14304. doi:10.4088/JCP.21m14304